The Centers for Medicare & Medicaid Services (CMS) posts quarterly updates of the HCPCS Level II code system on their website. Additionally, six codes are revised and 12 are discontinued, effective April 1, 2021. There are also two codes with changes to Medicare coverage. Following are the changes.
Code
A9592 Copper cu-64, dotatate, diagnostic, 1 millicurie
C9074 Injection, lumasiran, 0.5 mg
C9777 Esophageal mucosal integrity testing by electrical impedance, transoral (list separately in addition to code for primary procedure)
G2020 Services for high intensity clinical services associated with the initial engagement and outreach of beneficiaries assigned to the sip component of the pcf model (do not bill with chronic care management codes)
G2172 All inclusive payment for services related to highly coordinated and integrated opioid use disorder (oud) treatment services furnished for the demonstration project
J1427 Injection, viltolarsen, 10 mg
J1554 Injection, immune globulin (asceniv), 500 mg
J7402 Mometasone furoate sinus implant, (sinuva), 10 micrograms
J9037 Injection, belantamab mafodontin-blmf, 0.5 mg
J9349 Injection, tafasitamab-cxix, 2 mg
K1013 Enema tube, any type, replacement only, each
K1014 Addition, endoskeletal knee-shin system, 4 bar linkage or multiaxial, fluid swing and stance phase control
K1015 Foot, adductus positioning device, adjustable
K1016 Transcutaneous electrical nerve stimulator for electrical stimulation of the trigeminal nerve
K1017 Monthly supplies for use of device coded at k1016
K1018 External upper limb tremor stimulator of the peripheral nerves of the wrist
K1019 Monthly supplies for use of device coded at k1018
K1020 Non-invasive vagus nerve stimulator
M0245* Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring
Q0245* Injection, bamlanivimab and etesevimab, 2100 mg
Q2053 Brexucabtagene autoleucel, up to 200 million autologous anti-cd19 car positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose
S1091 Stent, non-coronary, temporary, with delivery system (propel)
Revised HCPCS Level II Codes
C9761* Cystourethroscopy, with ureteroscopy and/or pyeloscopy, with lithotripsy, and ureteral catheterization for steerable vacuum aspiration of the kidney, collecting system, ureter, bladder, and urethra if applicable
G9868 Receipt and analysis of remote, asynchronous images for dermatologic and/or ophthalmologic evaluation, for use only in a medicare-approved cmmi model, less than 10 minutes
G9869 Receipt and analysis of remote, asynchronous images for dermatologic and/or ophthalmologic evaluation, for use only in a medicare-approved cmmi model, 10-20 minutes
G9870 Receipt and analysis of remote, asynchronous images for dermatologic and/or ophthalmologic evaluation, for use only in a medicare-approved cmmi model, more than 20 minutes
J7321 Hyaluronan or derivative, hyalgan, supartz or visco-3, for intra-articular injection, per dose
Discontinued HCPCS Level II Codes
The following codes are discontinued effective April 1, 2021:
C9068 Copper cu-64, dotatate, diagnostic, 1 millicurie
C9069 Injection, belantamab mafodontin-blmf, 0.5 mg
C9070 Injection, tafasitamab-cxix, 2 mg
C9071 Injection, viltolarsen, 10 mg
C9072 Injection, immune globulin (asceniv), 500 mg
C9073 Brexucabtagene autoleucel, up to 200 million autologous anti-cd19 car positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose
C9122 Mometasone furoate sinus implant, 10 micrograms (sinuva)
J7333 Hyaluronan or derivative, visco-3, for intra-articular injection, per dose
J7401 Mometasone furoate sinus implant, 10 micrograms
K1010 Indwelling intraurethral drainage device with valve, patient inserted, replacement only, each
K1011 Activation device for intraurethral drainage device with valve, replacement only, each
K1012 Charger and base station for intraurethral activation device, replacement only
Reference:
https://www.aapc.com/blog/64702-april-updates-bring-hcpcs-changes/
